PUBLIC COMPANY
save$CGTXCOGNITION THERAPEUTICS INC
$CGTXPurchase, NY, USupdated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
- —Expanded Access Program for CT1812 (Zervimesine)
- phase2A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
- phase2A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
- phase2Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
- phase2Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
- phase2Effect of CT1812 Treatment on Brain Synaptic Density
- phase1Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects
🐶 Hiring Signal
News
- CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’sBiogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…biospace · 1d ago
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that